Literature DB >> 11791178

Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells.

Srinivas Venkateswarlu1, Dawn M Dawson, Patricia St Clair, Anjana Gupta, James K V Willson, Michael G Brattain.   

Abstract

The aim of this study was to determine whether constitutive ErbB2 activation controls growth and apoptosis in colon cancer cells. Growth arrested GEO cells showed constitutive activation of ErbB2 in the absence of exogenous growth factors or serum supplementation. Higher levels of heregulin and ErbB2 activation were observed in the growth-arrested state and cell cycle re-entry was independent of exogenous growth factors. Blockade of ErbB2 activation by heregulin neutralizing antibodies and by AG879 resulted in prevention of cell cycle re-entry. This indicated that autocrine heregulin activity was responsible for growth factor independence and for cell cycle re-entry. Activation of ErbB2 was the result of heregulin mediated interaction with ErbB3 and generated downstream activation of the ERK and the PI3K/AKT pathways. Heregulin neutralizing antibody treatment of growth arrested GEO cells also generated apoptosis as reflected by PARP cleavage and DNA fragmentation indicating a cell survival signal was also induced by the constitutively activated ErbB2. The activation of AKT but not the MAPK pathway was responsible for cell survival in these cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11791178     DOI: 10.1038/sj.onc.1205011

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  18 in total

1.  ErbB3 expression promotes tumorigenesis in pancreatic adenocarcinoma.

Authors:  J Spencer Liles; Juan Pablo Arnoletti; Ching-Wei D Tzeng; J Harrison Howard; Andrew V Kossenkov; Peter Kulesza; Martin J Heslin; Andrey Frolov
Journal:  Cancer Biol Ther       Date:  2010-09-30       Impact factor: 4.742

2.  Potentiation of colon cancer susceptibility in mice by colonic epithelial PPAR-δ/β overexpression.

Authors:  Xiangsheng Zuo; Min Xu; Jiang Yu; Yuanqing Wu; Micheline J Moussalli; Ganiraju C Manyam; Sun Il Lee; Shoudan Liang; Mihai Gagea; Jeffrey S Morris; Russell R Broaddus; Imad Shureiqi
Journal:  J Natl Cancer Inst       Date:  2014-03-28       Impact factor: 13.506

3.  Trans-10,cis-12, not cis-9,trans-11, conjugated linoleic acid decreases ErbB3 expression in HT-29 human colon cancer cells.

Authors:  Han Jin Cho; Woo Kyoung Kim; Jae In Jung; Eun Ji Kim; Soon Sung Lim; Dae Young Kwon; Jung Han Yoon Park
Journal:  World J Gastroenterol       Date:  2005-09-07       Impact factor: 5.742

Review 4.  Roles for neuregulins in human cancer.

Authors:  Christophe Stove; Marc Bracke
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

Review 5.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

6.  Identification of novel small-molecule compounds that inhibit the proproliferative Kruppel-like factor 5 in colorectal cancer cells by high-throughput screening.

Authors:  Agnieszka B Bialkowska; Yuhong Du; Haian Fu; Vincent W Yang
Journal:  Mol Cancer Ther       Date:  2009-02-24       Impact factor: 6.261

Review 7.  Autocrine stimulation in colorectal carcinoma (CRC): positive autocrine loops in human colorectal carcinoma and applicable significance of blocking the loops.

Authors:  Wen-Jing Ruan; Mao-De Lai
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

8.  Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.

Authors:  Wei-Jiang Zhao; Guan-Yong Ou; Wen-Wen Lin
Journal:  Front Immunol       Date:  2021-05-13       Impact factor: 7.561

9.  Expression of NRG1 and its receptors in human bladder cancer.

Authors:  J A Forster; A B Paul; P Harnden; M A Knowles
Journal:  Br J Cancer       Date:  2011-03-01       Impact factor: 7.640

Review 10.  The promise of anti-ErbB3 monoclonals as new cancer therapeutics.

Authors:  Luigi Aurisicchio; Emanuele Marra; Giuseppe Roscilli; Rita Mancini; Gennaro Ciliberto
Journal:  Oncotarget       Date:  2012-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.